AFM
ONCT

Anson Funds Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Anson Funds Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,894
Closed -$207K – 58
2018
Q4 		$207K Buy
+1,894
New +$379K 0.12% 39

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Anson Funds Management's ONCT Position: Q1 2019 in Review

Anson Funds Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 1,894 shares — an estimated $207K sold.

Anson Funds Management first reported a position in ONCT in Q4 2018 and held it in 1 quarter. The position peaked at $207K in Q4 2018. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

  • Anson Funds Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 1,894 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $207K.
  • Anson Funds Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $207K in Q4 2018.
  • 35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.